3D Printed Praziquantel Formulations via Direct Powder Extrusion for the Treatment of Schistosomiasis – Scientific Poster
The 12th APV PBP World Meeting took place from 28 – 31 March 2022 in Rotterdam. There was a poster section at the event where really interesting scientific posters were presented. Therefore we asked the presenting scientists if we could share their work in addition online with the Pharma Excipients community.
As many scientists send us their posters we will show several posters of the PBP Poster Session stepwise over the next weeks.
The next poster in our series is from Patricija Januskaite from UCL, London:
(click on the poster to enlarge it)
A disorder caused by parasitic worms, schistosomiasis, affects around 250 million people worldwide and results in the highest mortality rates in developing countries . The current standard treatment, praziquantel (PZQ), has no licensed formulation on the market for paediatric patients [2,3]. PZQ treatment for children involves the off-label use and dose adjustment via tablet splitting, resulting in dosing errors and dangerous side effects or absence of medicine effectiveness, and the bitter taste of PZQ is also rejected by many patients when taste buds are exposed due to the splitting of tablets.
Different compositions were tested and printed: powder from milled HME pellets (M) consisting of crystalline racemic PZQ (Fiocruz, Brazil) and Kollidon® VA 64 (KOL), Kolliphor® SLS Fine (SLS) (BASF, Ludwigshafen, Germany), or Span™ 20 (Span) (Croda International, UK) (Table 1).
Download the poster as PDF here: 3D Printed Praziquantel Formulations via Direct Powder Extrusion
Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX
See the first poster in our series: